Return to List
Study Summary
No.
2008-0847:
.......
Endocrine; Head And Neck; Laboratory; Thyroid
......
Steven I. Sherman
......
Endocrine Neoplasia & Hormonal Disorders
.
Study Summary Title
Study Summary
Number:
2008-0847
Study Title:
Circulating Tumor Cells in Thyroid Carcinomas
.
Physician
New Patient Referral
Name:
Steven I. Sherman
Patients Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Dept:
Endocrine Neoplasia & Hormonal Disorders
Referring MD
Call:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Phone:
713-792-2841
Contact us about clinical trials
.
General Information
Disease Group:
Endocrine
Head And Neck
Laboratory
Thyroid
Supported By:
Institute for Personalized Cancer Therapy
V Coundation for Cancer Research
Phase of Study:
N/A
Return
Visit:
Not applicable
Treatment
Agents:
None
Home Care:
None
Treatment Loc:
Only at MDACC
Estimated
Length of Stay
in Houston:
Not applicable
Description/
Intervention:
The goal of this laboratory research study is to design a blood test that will
detect thyroid cancer cells that may be circulating in the blood stream of
patients with thyroid cancer.
.
Study Objectives / Outcomes
To demonstrate that the Veridex CellSearch™ assay can detect circulating tumor cells in patients with differentiated and medullary thyroid carcinomas.
.
Study Status Information
Study Activation / Registration Date:
05/22/2009
IRB Review and Approval Date:
05/22/2009
Study Type:
Laboratory
Recruitment Status:
Closed
Projected Accrual:
N/A
.
Enrollment Eligibility
If you do not meet the enrollment eligibility, there may be other treatment options for you.
Please Contact the
Referral Office
for more information.
Inclusion Criteria:
1) patients with newly diagnosed (by FNA) DTC or MTC before primary surgical therapy (10 patients per histologic subtype)
2) patients with DTC or MTC, but no evidence of residual disease by standard biochemical and clinical criteria for at least 5 years (10 patients per histologic subtype)
3) patients with radiographic evidence of extracervical metastatic DTC or MTC who have already had primary surgery for locoregional disease (20 patients per histologic subtype)
Exclusion Criteria:
1) they do not sign informed consent
2) they are felt by their physician to be too ill to tolerate phlebotomy for an extra 20 mL of whole blood for research purpose
3) they have had any evidence of or have been treated for any other malignant disease within the past 5 years
.
Links
Registration Number:
Not Applicable Clinical Trial
Other Links:
.
Results
Return to Clinical Trials at M.D. Anderson Cancer Center